| Literature DB >> 28052733 |
Ning An1, Yaozhen Chen1, Dandan Yin2, Hui-Jie Zhang1, Zheng Liu3, Fan Feng4, Na Li1, Jiajia Xin1, Wen Yin1, Xueqing Xu5, Xingbin Hu1.
Abstract
The intrinsic basis of cancer-related anemia (CRA) is erythropoiesis disorder, which is a common complication of cancer and exerts a negative influence on the life quality of cancer patients. Cell therapy using mesenchymal stromal cells (MSCs) is considered as a promising method in cancer treatment. Furthermore, MSCs have been used to cure few type of anemia and be considered as a potential strategy to recover anemia radically. However, none reports its application in CRA treatment. In CRA model mice, we found that the number of lin-c-kit+Sca-1+ and Sca-1+ MSCs was decreased. And CRA resulted in an increased number of proerythroblasts and basophilic erythroblasts and decreased number of orthochromatic erythroblasts. Furthermore, in CRA model mice transplanted with Sca-1+ MSCs and MSCs, the levels of red blood cell count and Hb in peripheral blood were obviously increased. And the accumulation of proerythroblasts and basophilic erythroblasts was inhibited. In addition, the expression patterns of GATA-1 and GATA-2, which is pivotal to anemia, were remarkably recovered. Our results demonstrated that either MSCs or its subpopulation could effectively recover CRA erythropoiesis through GATA-1/GATA-2 signaling, which outstrips the traditional symptomatic therapy.Entities:
Keywords: MSCs; Sca-1+ MSC subpopulation; cancer-related anemia; erythropoiesis; melanoma
Mesh:
Year: 2017 PMID: 28052733 DOI: 10.1089/scd.2016.0139
Source DB: PubMed Journal: Stem Cells Dev ISSN: 1547-3287 Impact factor: 3.272